Characteristics of the study population
| No COPD (n=98) | UCOPD (n=39) | p-value | |
| Age years | 63±11 | 69±8 | <0.01 |
| Male n (%) | 83 (85) | 32 (82) | 0.8 |
| BMI k·m−2 | 28±4 | 27±4 | 0.2 |
| Diabetes n (%) | 21 (21) | 11 (28) | 0.5 |
| Hypertension n (%) | 67 (68) | 25 (64) | 0.7 |
| Hyperlipidaemia n (%) | 55 (56) | 17 (44) | 0.2 |
| Current smoker n (%) | 44 (45) | 17 (44) | 0.9 |
| Previous smoker n (%) | 54 (55) | 22 (56) | |
| Prior MI n (%) | 16 (16) | 8 (21) | 0.3 |
| Prior PCI n (%) | 18 (18) | 6 (15) | 0.8 |
| Prior CABG n (%) | 5 (5) | 2 (5) | 0.9 |
| STEMI n (%) | 40 (41) | 19 (49) | 0.6 |
| LVEF % | 52±9 | 50±9 | 0.2 |
| Laboratory data at baseline | |||
| White blood cells u·μL−1 | 10±3 | 11±3 | 0.7 |
| Haemoglobin g·dL−1 | 13±2 | 13±2 | 0.6 |
| Platelets u·μL−1 | 227 [189–266] | 223 [192–280] | 0.6 |
| Cardiovascular therapy n (%) | |||
| Aspirin | 97 (99) | 39 (100) | 0.9 |
| Ticagrelor | 55 (56) | 20 (52) | 0.6 |
| Other P2Y12 inhibitor | 43 (44) | 19 (48) | |
| Clopidogrel | 33 (34) | 14 (36) | 0.8 |
| Prasugrel | 10 (10) | 5 (12) | 0.8 |
| Beta-blocker | 84 (86) | 35 (90) | 0.8 |
| ACE inhibitor/ARB | 88 (90) | 37 (95) | 0.5 |
| Statin | 96 (98) | 37 (95) | 0.3 |
| Calcium channel blockers | 5 (5) | 2 (5) | 0.9 |
| Nitrates | 2 (2) | 1 (2) | 0.9 |
| Proton pump inhibitor# | 51 (52) | 20 (51) | 0.9 |
| Biological parameters % | |||
| Rate of apoptosis | 9.2±4 | 13.2±3 | <0.001 |
| Patients receiving ticagrelor | 7.7±3 | 12.2±2 | <0.001 |
| Patients receiving other P2Y12 inhibitors | 11.1±5 | 14.2±3 | 0.0004 |
| On-treatment PR after ADP stimulus | 32±14 | 42±17 | <0.001 |
| Patients receiving ticagrelor | 24±11 | 28±9 | 0.3 |
| Patients receiving other P2Y12 inhibitors | 41±11 | 57±7 | <0.001 |
| On-treatment PR after AA stimulus | 14±21 | 22±20 | <0.001 |
Data are presented as mean±sd, unless otherwise stated.#: pantoprazole was the only proton pump inhibitor administered. COPD: chronic obstructive pulmonary disease; UCOPD: undiagnosed/unknown COPD; BMI: body mass index; MI: myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; STEMI: ST-segment elevation MI; LVEF: left ventricular ejection fraction; ACE: angiotensin converting enzyme; ARB: angiotensin II receptor blocker; PR: platelet reactivity; ADP: adenosine diphosphate; AA: arachidonic acid.